BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21214406)

  • 1. P-glycoprotein expression, tumor weight, age, and relapse in patients with stage I and II favorable-histology Wilms' tumor.
    Teixeira RA; Odone-Filho V; de Camargo B; Zerbini MC; Fillipi R; Alencar A; Cristofani L
    Pediatr Hematol Oncol; 2011 Apr; 28(3):194-202. PubMed ID: 21214406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapse of unilateral favorable histology Wilms' tumor: significant clinicopathological factors.
    Aoba T; Urushihara N; Fukumoto K; Furuta S; Fukuzawa H; Mitsunaga M; Watanabe K; Yamoto M; Miyake H; Koyama M; Iwabuchi H; Koike J; Tatsunami S; Wakisaka M; Kitagawa H
    J Pediatr Surg; 2012 Dec; 47(12):2210-5. PubMed ID: 23217878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased microvascular density predicts relapse in Wilms' tumor.
    Abramson LP; Grundy PE; Rademaker AW; Helenowski I; Cornwell M; Katzenstein HM; Reynolds M; Arensman RM; Crawford SE
    J Pediatr Surg; 2003 Mar; 38(3):325-30; discussion 325-30. PubMed ID: 12632343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of p53 expression in Wilms' tumor in children.
    Skotnicka-Klonowicz G; Kobos J; Łoś E; Trejster E; Szymik-Kontorowicz S; Daszkiewicz P
    Med Sci Monit; 2001; 7(6):1224-9. PubMed ID: 11687734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wilms' tumor at the Children's Hospital of Eastern Ontario: 1990-2001.
    Pianezza ML; Rubin S; Bass J; Chou S; Pike JG; Leonard MP
    Can J Urol; 2004 Feb; 11(1):2151-6. PubMed ID: 15003157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late recurrence in children with Wilms' tumor.
    Büyükpamukçu M; Köksal Y; Varan A; Atahan L; Cağlar M; Akyüz C; Kutluk T; Büyükpamukçu N
    Turk J Pediatr; 2007; 49(2):226-30. PubMed ID: 17907529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 immunopositivity in histologically favorable Wilms tumor is not related to stage at presentation or to biological aggression.
    D'Angelo MF; Kausik SJ; Sebo TJ; Rathbun SR; Kramer SA; Husmann DA
    J Urol; 2003 May; 169(5):1815-7. PubMed ID: 12686851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
    Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
    J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic relevance of preoperative transcatheter arterial chemoembolization (TACE) and PCNA/VEGF expression in patients with Wilms' tumour.
    Liu WG; Gu WZ; Zhou YB; Tang HF; Li MJ; Ma WX
    Eur J Clin Invest; 2008 Dec; 38(12):931-8. PubMed ID: 19021718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 23-year experience with malignant renal tumors in infancy and childhood.
    Tröbs RB; Hänsel M; Friedrich T; Bennek J
    Eur J Pediatr Surg; 2001 Apr; 11(2):92-8. PubMed ID: 11371043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
    Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
    J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms' tumor.
    Dome JS; Bockhold CA; Li SM; Baker SD; Green DM; Perlman EJ; Hill DA; Breslow NE
    J Clin Oncol; 2005 Dec; 23(36):9138-45. PubMed ID: 16172460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.
    Dome JS; Cotton CA; Perlman EJ; Breslow NE; Kalapurakal JA; Ritchey ML; Grundy PE; Malogolowkin M; Beckwith JB; Shamberger RC; Haase GM; Coppes MJ; Coccia P; Kletzel M; Weetman RM; Donaldson M; Macklis RM; Green DM
    J Clin Oncol; 2006 May; 24(15):2352-8. PubMed ID: 16710034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical detection of p53 protein expression as a prognostic factor in Wilms tumor.
    Jadali F; Sayadpour D; Rakhshan M; Karimi A; Rouzrokh M; Shamsian BS; Shamshiri AR
    Iran J Kidney Dis; 2011 Jul; 5(3):149-53. PubMed ID: 21525573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonviable tumor tissue should not upstage Wilms' tumor from stage I to stage II: a report from the SIOP 93-01 nephroblastoma trial and study.
    Vujanić GM; Harms D; Bohoslavsky R; Leuschner I; de Kraker J; Sandstedt B
    Pediatr Dev Pathol; 2009; 12(2):111-5. PubMed ID: 18811224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of proto-oncogene Bcl-X(S/L) expression in Wilms tumor.
    Basta-Jovanović G; Radonjic V; Stolic I; Nenadovic M; Brasanac D; Jovanovic D; Radojevic-Skodric S
    Ren Fail; 2005; 27(1):13-8. PubMed ID: 15717629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor.
    Dome JS; Chung S; Bergemann T; Umbricht CB; Saji M; Carey LA; Grundy PE; Perlman EJ; Breslow NE; Sukumar S
    Cancer Res; 1999 Sep; 59(17):4301-7. PubMed ID: 10485476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome after pulmonary radiotherapy in Wilms' tumor patients with pulmonary metastases at diagnosis: a UK Children's Cancer Study Group, Wilms' Tumour Working Group Study.
    Nicolin G; Taylor R; Baughan C; Shannon R; Stevens S; Richardson D; Kelsey A; Pritchard-Jones K; Mitchell C
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):175-80. PubMed ID: 17980506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical analysis of gamma catenin in Wilms' tumors.
    Basta-Jovanovic G; Gvozdenovic E; Dimitrijevic I; Brasanac D; Jovanovic M; Kalezic N; Baralic I; Radojevic-Skodric S; Arsic D
    Fetal Pediatr Pathol; 2008; 27(2):63-70. PubMed ID: 18568994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B7-h1 as a biomarker for therapy failure in patients with favorable histology Wilms tumor.
    Routh JC; Grundy PE; Anderson JR; Retik AB; Kurek KC
    J Urol; 2013 Apr; 189(4):1487-92. PubMed ID: 23154206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.